Researchers at Baylor College of Medicine are recruiting volunteers for a clinical trial to test an oral targeted therapy for patients with metastatic cervical cancer. They are looking for women age 18 and older with stage IV cervical cancer who have completed three to six treatments of carbo/taxol with clinical evidence of complete or partial response.

Participants will receive up to six cycles of first-line intravenous chemotherapy (carboplatin and paclitaxel) followed by radiation and oral targeted therapy (niraparib). The volunteers will either receive 100 mg or 200 mg of niraparib along with standard-of-care radiation therapy over the course of 8 weeks. Researchers will measure the maximum tolerated dose of niraparib when administered with radiotherapy, the acute toxicity profile of niraparib and will measure the local progression free survival. Upon completion of the treatment, tumor response will be measured every 3 months for up to 5 years.

For more information or to enroll, contact Dr. Michelle Ludwig at 713-566-3757 or by email at michelle.ludwig@bcm.edu. Find out more about this trial or Baylor’s other cervical cancer clinical trials.